The 18-month study will determine patients' rates of warfarin-related adverse events at 30, 60 and 90 days from initial warfarin dosing. Study results will be used by CMS for reimbursement decision-making. The multicenter, randomized, blinded, parallel-group study is being led by Principal Investigator Elizabeth Ofili, M.D., Chief of Cardiology, Director of Clinical Research, and Associate Dean for Clinical Research at Morehouse School of Medicine. Trial registration and study sites can be found at www.warfarinstudy.org.
"This landmark study is about more than warfarin," said Dean Sproles, CEO and Chairman, Iverson Genetic Diagnostics Inc., which initiated the WARFARIN Study. "It is about individualizing treatment to improve patient safety and outcomes, thereby reducing healthcare costs. CMS' support of the WARFARIN Study demonstrates their commitment to exploring the impact of genetic testing on individualized dosing, which may pave the way for other studies in the personalized medicine arena."
In related news, Mr. Sproles will make a presentation on March 2, 2011, about the newly-launched WARFARIN Study at the 11th Annual Life Science Innovation Northwest Conference, sponsored by the Washington Biotechnology & Biomedical Association (WBBA) in partnership with Burrill & Co. He will present at 2:35 pm in Room 608, Washington State Convention Center, Seattle, WA.
About Iverson Genetic Diagnostics, Inc.Iverson Genetic Diagnostics, Inc. provides physicians with genetics-based testing to identify ind
|SOURCE Iverson Genetic Diagnostics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved